Latest Diagnostics News

Monash IVF Group has appointed Dr Victoria Atkinson as its new Managing Director and CEO, effective May 2026, signaling a strategic leadership shift for the assisted reproductive services provider.

Optiscan Imaging has entered a three-year strategic collaboration with Australian Clinical Labs to validate and deploy its InForm™ digital pathology platform, aiming to transform diagnostic workflows with real-time tissue analysis.

Archer Materials has partnered with CSIRO to develop cutting-edge quantum machine learning models aimed at revolutionizing fraud detection in financial transactions.

Integral Diagnostics has appointed Jason Martinez as its new CEO, set to lead the company’s growth and innovation efforts starting in 2026. Martinez brings over two decades of diagnostic imaging leadership experience, promising a strategic focus on expansion and operational excellence.

Proteomics International secures half a million dollars from the Western Australian Government to accelerate commercialisation of PromarkerEndo, a groundbreaking blood test for early endometriosis diagnosis.

Cleo Diagnostics has identified a significantly larger U.S. patient population for its pre-surgical ovarian cancer test, expanding its commercial opportunity ahead of next year’s market entry.

Artrya secures participation from Mass General Brigham, a leading U.S. cardiovascular research center, in its pivotal SAPPHIRE Study launching in early 2026. This collaboration aims to validate Artrya’s AI-powered Salix platform for earlier and more effective coronary artery disease detection.

Imagion Biosystems reports encouraging findings from its Wayne State University collaboration, supporting a lower dose for its MagSense® HER2 imaging agent ahead of a planned FDA IND submission in Q4 2025.

TrivarX Limited has exercised its option to acquire the innovative Stabl-Im brain imaging technology, aiming to revolutionize early detection of brain tumours pending shareholder approval.

Cleo Diagnostics has secured positive FDA feedback and nearly 1,600 biobank samples, accelerating its ovarian cancer blood test development ahead of a planned 2026 U.S. market entry.

Omega Oil and Gas has bolstered its balance sheet with a $46 million equity placement and confirmed the strong commercial potential of its Canyon Project, setting the stage for a major appraisal campaign in 2026.

Nexsen Limited has successfully completed an $8 million IPO and ASX listing, while advancing its kidney diagnostic tests and initiating clinical trials for its GBS Rapid Sensor targeting expedited FDA approval.